Naldemedine
Naldemedine (brand name Symproic in the US and Rizmoic in Europe) is a drug which is approved for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. It is a peripherally acting μ-opioid receptor antagonist and was developed by Shionogi. Clinical studies have found it to possess statistically significant effectiveness for these indications and to be generally well tolerated, with predominantly mild to moderate gastrointestinal side effects. Effects indicative of central opioid withdrawal or impact on the analgesic or miotic effects of co-administered opioids have only been observed in a small number of patients. Medical uses In the US, naldemedine is approved for the treatment of opioid induced constipation in adults with chronic non-cancer pain, including those who have chronic pain related to prior cancer or its treatment and do not need frequent opioid dosage escalation.In Europe, naldemedine is also approved for the treatment of opioid induced constipation in adults, but as a second-line therapy after treatment with a laxative. Contraindications The drug is contraindicated in patients with gastrointestinal obstruction or perforation, or those at risk for these problems. Side effects Side effects in studies were abdominal pain (8–11% of patients as compared to 2–5% under placebo, 